{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "64-year-old man admitted in October 2021 with exertional dyspnea and hypoxia.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "64-year-old man admitted with exertional dyspnea and hypoxia.",
              "onset": "October 2021",
              "associated_symptoms": [
                "Dyspnea",
                "Hypoxia"
              ],
              "exacerbating_factors": [
                "Exertion"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Diagnosis: Adenocarcinoma subtype NSCLC with metastases to the lungs, liver, and brain. AKIF5B-RETfusion confirmed by RNA-based multitarget next-generation sequencing panel. Programmed death-ligand 1 (PD-L1) expression was 35%.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Adenocarcinoma of lung",
              "status": "active"
            },
            {
              "code": "C78.0",
              "label": "Secondary malignant neoplasm of lung",
              "status": "active"
            },
            {
              "code": "C78.7",
              "label": "Secondary malignant neoplasm of liver",
              "status": "active"
            },
            {
              "code": "C79.31",
              "label": "Secondary malignant neoplasm of brain",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "PD-L1 Expression",
              "value": "35",
              "unit": "%",
              "flag": "unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Medical history of transient ischemic attack and 5 pack-year smoking history. Prior treatment included three cycles of carboplatin, pemetrexed, and pembrolizumab to partial response and 12 months of second-line pralsetinib, with partial response. Three small-volume brain metastases (largest lesion 7 mm, left parietal lobe) had been present at baseline and previously responded to pralsetinib without requirement for radiation therapy. Three prior episodes of low-grade (maximum grade 2) pralsetinib-related pneumonitis between November 2020 and April 2021 had been managed with oral steroids, treatment interruption, and dose reduction (400 mg once daily to 200 mg once daily).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "422587000",
              "label": "Transient ischaemic attack",
              "status": "historical"
            },
            {
              "code": "C0006826",
              "label": "Brain Metastasis",
              "status": "active"
            }
          ],
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "5 pack-year smoking history"
            }
          ],
          "medications": [
            {
              "drug": "C0698786",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "C0006826"
            },
            {
              "drug": "C1641302",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "C0006826"
            },
            {
              "drug": "C4728447",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "C0006826"
            },
            {
              "drug": "C4043403",
              "dosage": "400 mg once daily to 200 mg once daily",
              "frequency": "once daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "C0006826"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "CTPA: multiple lung metastases and multifocal ground-glass changes consistent with pneumonitis; nil evidence of infection or pulmonary embolus. Neutrophil count, white blood cell count, and C-reactive protein level were within reference range; no pyrexia or sputum production. High-flow oxygen and 1 mg/kg oral prednisolone were commenced for treatment of grade 3 drug-related pneumonitis. Pralsetinib was suspended. Baseline axial and coronal CT imaging revealed multifocal ground-glass opacification in keeping with pralsetinib-related pneumonitis.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Pulmonary CT Angiography",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "multiple lung metastases and multifocal ground-glass changes consistent with pneumonitis; nil evidence of infection or pulmonary embolus",
              "impression": "multiple lung metastases and multifocal ground-glass changes consistent with pneumonitis; nil evidence of infection or pulmonary embolus",
              "date": null
            },
            {
              "type": "Computed tomography",
              "body_part": "lung",
              "modality": "CT",
              "finding": "multifocal ground-glass opacification",
              "impression": "multifocal ground-glass opacification in keeping with pralsetinib-related pneumonitis.",
              "date": null
            }
          ],
          "labs": [
            {
              "test": "Neutrophil count",
              "value": "within reference range",
              "unit": null,
              "flag": "normal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "White blood cell count",
              "value": "within reference range",
              "unit": null,
              "flag": "normal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "C-reactive protein level",
              "value": "within reference range",
              "unit": null,
              "flag": "normal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "vitals": [
            {
              "type": "Pyrexia",
              "value": "no",
              "unit": null,
              "timestamp": null
            }
          ],
          "medications": [
            {
              "drug": "Prednisolone",
              "dosage": "1 mg/kg",
              "frequency": null,
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "drug-related pneumonitis"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient progressed from initial presentation of exertional dyspnea and hypoxia to diagnosis of Adenocarcinoma subtype NSCLC with metastases to the lungs, liver, and brain. AKIF5B-RETfusion confirmed by RNA-based multitarget next-generation sequencing panel. Programmed death-ligand 1 (PD-L1) expression was 35%."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Patient's medical history and prior treatments are reviewed, including transient ischemic attack, smoking history, prior cycles of carboplatin, pemetrexed, and pembrolizumab, and second-line pralsetinib. History of brain metastases and pralsetinib-related pneumonitis is noted.",
        "transition_event": {
          "trigger_type": "interpretation",
          "trigger_entities": [
            "C0006826",
            "C4043403"
          ],
          "change_type": "other",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Patient developed grade 3 drug-related pneumonitis, leading to the commencement of high-flow oxygen and oral prednisolone, and suspension of pralsetinib. CTPA revealed multiple lung metastases and multifocal ground-glass changes consistent with pneumonitis. No evidence of infection or pulmonary embolus. Neutrophil count, white blood cell count, and C-reactive protein level were within reference range; no pyrexia or sputum production.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0025598"
          ],
          "change_type": "progression",
          "target_domain": "symptom"
        }
      }
    }
  ]
}